Back to Search Start Over

Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.

Authors :
Sconocchia G
Lanzilli G
Cesarini V
Silvestris DA
Rezvani K
Arriga R
Caratelli S
Chen K
Dou J
Cenciarelli C
Toietta G
Baldari S
Sconocchia T
De Paolis F
Aureli A
Iezzi G
Irno Consalvo M
Buccisano F
Del Principe MI
Maurillo L
Venditti A
Ottaviani A
Spagnoli GC
Source :
Life science alliance [Life Sci Alliance] 2022 Oct 14; Vol. 5 (12). Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2022).
Publication Year :
2022

Abstract

The FcγRII (CD32) ligands are IgFc fragments and pentraxins. The existence of additional ligands is unknown. We engineered T cells with human chimeric receptors resulting from the fusion between CD32 extracellular portion and transmembrane CD8α linked to CD28/ζ chain intracellular moiety (CD32-CR). Transduced T cells recognized three breast cancer (BC) and one colon cancer cell line among 15 tested in the absence of targeting antibodies. Sensitive BC cell conjugation with CD32-CR T cells induced CD32 polarization and down-regulation, CD107a release, mutual elimination, and proinflammatory cytokine production unaffected by human IgGs but enhanced by cetuximab. CD32-CR T cells protected immunodeficient mice from subcutaneous growth of MDA-MB-468 BC cells. RNAseq analysis identified a 42 gene fingerprint predicting BC cell sensitivity and favorable outcomes in advanced BC. ICAM1 was a major regulator of CD32-CR T cell-mediated cytotoxicity. CD32-CR T cells may help identify cell surface CD32 ligand(s) and novel prognostically relevant transcriptomic signatures and develop innovative BC treatments.<br /> (© 2022 Sconocchia et al.)

Details

Language :
English
ISSN :
2575-1077
Volume :
5
Issue :
12
Database :
MEDLINE
Journal :
Life science alliance
Publication Type :
Academic Journal
Accession number :
36241426
Full Text :
https://doi.org/10.26508/lsa.202201590